FCFrancesca Canellas

Francesca Canellas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Francesca Canellas has a total of 105 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sleep Disturbances and Circadian Phase Delay in People Living with Human Immunodeficiency Virus (HIV): A Systematic Review

    by Antoni Gomila-Cardona, Saúl Ferrández-Sempere, Francesca Cañellas, Antoni Gamundí, Mourad Akaârir, Cristina Nicolau, José Ángel Rubiño-Díaz

    Advances in HIV research and antiretroviral therapy (ART) have substantially increased life expectancy among people living with HIV (PLHIV). However, challenges affecting quality of life and alterations in daily physiological processes persist. Among the health dimensions most affected are sleep quality and circadian rhythms, resulting in significant biological alterations. The main objective of this study is to analyze the existing scientific evidence regarding the effects of HIV on sleep quality and on the alignment and synchronization of circadian rhythms. The bidirectional interaction between these physiological alterations and associated clinical, immunological, and metabolic factors in people living with HIV (PLHIV) was evaluated, emphasizing their integration. For this review, searches were conducted in the PubMed, Scopus, and Web of Science databases. Eligibility criteria were applied, resulting in a final selection of 15 studies based on search strategies. The findings demonstrated a high prevalence of poor sleep quality as well as delayed circadian phase. These chronobiological alterations were closely associated with systemic inflammation, altered melatonin levels, impaired cognitive performance, and an altered metabolic profile involving leptin, ghrelin, adiponectin, and peroxisome proliferator-activated receptor (PPAR) signaling. Despite the consistency of the results, the methodologies of individual studies varied, and a notable absence of clinical trials aimed at addressing poor sleep quality and chronodisruption was observed. A promising clinical approach involves complementing antiretroviral therapy (ART) with chronotherapeutic interventions and sleep hygiene. In conclusion, HIV can disrupt personal temporal organization at a systemic level; consequently, incorporating assessments of sleep and circadian rhythms into clinical care may be warranted, while chronotherapeutic interventions should be further investigated.

  • Open Access

    Exploration of Shift Work Among Nursing Professionals Related to Interconnected Determinants of Health in a Hospital: A Cross-Sectional Study

    by José Ángel Rubiño-Díaz, Saúl Ferrández-Sempere, Francesca Canellas, Antonio Gamundí, Mourad Akaârir, Cristina Nicolau

    Background: Nursing professionals must fulfill their care duties within a system that requires 24-hour coverage. This necessitates hospitals implementing a shift-work system to meet care demands. Purpose: To assess sleep quality and its relationship with interconnected health variables among nursing professionals working shifts. Method: A cross-sectional descriptive observational study. 247 nursing professionals, 85.8% of whom were women, aged between 21 and 65, from Son Espases University Hospital in Spain. A corporate email was sent containing a link to an online: the Pittsburgh Sleep Quality Index (PSQI), Munich Chronotype Questionnaire (MCTQ) to determine chronotype, the Perceived Stress Scale (PSS-14), General Health Questionnaire (GHQ-12), Memory Failures of Everyday Life Questionnaire (MFE-30), and the World Health Organization Quality of Life Questionnaire (WHOQOL-BREF), applied across different work shifts. Results: Nurses, regardless of shift work, reported poor sleep quality (score > 5), a higher proportion of undefined chronotype (60%), moderate levels of perceived stress (26 points), a tendency toward poorer general mental health (14 points), and more memory complaints (60 points), but a favorable perception of their quality of life (90 points), with no statistically significant differences found. Female professionals working rotating shifts showed significant differences, presenting a higher number of memory complaints compared with males. Professionals over the age of 50 working night shifts displayed significantly poorer general mental health and severe memory complaints. Conclusion/Implications for Practice: Nursing professionals show poor sleep quality, elevated stress levels, signs of emotional disorders, and moderate memory complaints, particularly on night and rotating shifts, which were observed, albeit without significantly affecting perceived quality of life. These findings support the need to implement organizational strategies that safeguard the well-being of nursing professionals and to consider individual patterns to improve sleep health.

  • Open Access

    Benefits of exposure to morning daylight on sleep, circadian rhythms, and symptoms of depression

    by José A. Rubiño, M.A. Cristina Nicolau, Anna Riera, Aida Martín, Francesca Cañellas

    Background: Current research has shown that depressive symptoms are associated with sleep disturbances and misalignment of circadian rhythms. Thus, a chronobiological intervention associated with the usual antidepressant treatment on depressive symptoms may improve depressive symptoms as long with sleep quality, and circadian rhythms in patients with depression. Methods: The feasibility experimental study was carried out with a total of 38 participants: 21 outpatients suffering from a non-seasonal major depressive disorder (MDD) and 17 healthy volunteers (general population). Twenty-one patients were randomly assigned to two groups: 11 patients received a chronobiological intervention: daylight exposure treatment for 14 days in conjunction with pharmacological treatment (LIGHT group), while 10 patients received only pharmacological treatment (LIGHT group). Depressive severity at the inclusion was assessed with the Montgomery-Asberg Depression Scale (MADRS), and the International Neuropsychiatric Interview (MINI) was used to exclude comorbid psychiatric disorders. The evolution of depressive symptoms was assessed using the Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR16). Patients' sleep was evaluated using, Munich Chronotype Questionnaire and with Pittsburgh Sleep Quality Index (PSQI) and sleep agenda. In addition, circadian parameters were assessed using Kronowise® device (KW6), and target sleep quality indices were calculated. Results: The intervention combining daylight exposure with pharmacological treatment demonstrated significant improvements in depressive symptoms. There was a noticeable trend towards subjective improvement in sleep quality. Data registered with the KW6 device indicated an improvement in motor activity and peripheral temperature rhythms. Conclusions: Depressive patients undergoing psychopharmacological treatment, who received a specific instruction to increase their exposure to daylight, improved their depressive symptoms, sleep quality, and circadian rhythms.

  • Open Access

    Insomnia Subtypes in Clinical Population According to the Insomnia Type Questionnaire ( ITQ ): A Multi‐Centre Study in Spanish Sleep Clinics

    by Francesca Canellas, Manuel de Entrambasaguas, Odile Romero, Ainhoa Álvarez, Rybel Wix, Francisco Javier Puertas, Jesús Pujol, Guillem Frontera

    The lack of robust subtyping for insomnia disorder (ID) led to its current classification as a uniform condition. A novel approach to subtyping ID developed a new tool, the insomnia type questionnaire (ITQ). Our research aimed to assess whether the ID subtypes identified in the general population could also be found in ID patients referred to sleep clinics in a multi‐centre study throughout Spain, and to gather insights for the management of complex ID patients. The ITQ classified ID patients into the five previously described subtypes: Type 1 = 35.1%, Type 2 = 12%, Type 3 = 46.7%, Type 4 = 5.8% and Type 5 = 0.4%. Compared to the general population, there was an overrepresentation of Types 1 and 3, consistently across all participating clinical centres. The total self‐reported sleep duration was 4.7 (SD 1.2) h, with no significant differences between subtypes. Type 1 patients had significantly higher scores in the Insomnia Severity Index, Inventory of Depressive Symptomatology self‐rated and State–Trait Anxiety Inventory. Type 3 patients were more worried about their sleep. Type 4 had the lowest depression and anxiety scores. ITQ subtyping showed that ID patients attending sleep clinics had high scores in depression, specially Type 1 patients, who probably need a differentiated therapeutic approach. The over‐representation of Type 3 patients suggests that they are more worried about their sleep than the other subtypes. These findings highlight the difficulties faced by sleep clinicians to treat complex and refractory‐toto‐treatment ID patients and those with comorbid insomnia.

  • Open Access

    Are patients with depression exposed to less light than healthy controls?

    by Aida Martín-Reina, Anna Riera-Gimeno, José Angel Rubiño, Maria Cristina Nicolau, Francesca Canellas

  • Open Access

    The Disputable Costs of Sleeping

    by Mourad Akaarir, M. Cristina Nicolau, Francesca Cañellas, Jose A. Rubiño, Pere Barceló, Antonio Gamundí, Aida Martin-Reina, Rubén V. Rial

    It is currently affirmed that sleep detracts from time for foraging, reproductive, and anti-predatory activities. In contrast, we show that the sleep-related reductions in food intake and reproductive activities may, in fact, be benefits. Furthermore, the present report shows that the optimal prey are the immature, weak, sick, and senescent animals and rarely the sleeping fit adults. Indeed, the reduced sleeping time observed in prey animals occurs, not because of an evolutionary antipredation pressure but because of the time-expensive foraging-related activities and the digestion of the high-cellulose content in the herbivores’ diet, an activity that leaves reduced amounts of daily time for sleeping. We conclude that the need for sleep ranks lower than those of foraging, reproduction, and antipredation activities.


  • Open Access

    Associative Memory and Memory Complaints in People with First Episode of Depression: Use of the Face-Name Associative Memory Exam (FNAME)

    by José Ángel Rubiño, Aida Martín-Reina, M. Cristina Nicolau, Francesca Canellas, Juan Francisco Francisco Flores-Vazquez, Stefanie Enriquez-Geppert, Pilar Andrés

    Major depressive disorder (MDD) can lead to cognitive dysfunction. The objective is to assess associative episodic memory and subjective memory complaints in daily life in people with a first episode of depression (FED). Analytical observational design. Fifteen patients with FED mean age 50.20 (8.04) years and 15 healthy control (HCtrl) mean age 45.07 (8.64) years participants, both middle-aged adults, were assessed. The recruitment was from Mental Health Units in Mallorca, and this lasted between March 2021 to October 2022. DSM-5® diagnostic criteria and the Interna-tional Neuropsychiatric Interview (MINI) were used to diagnose depression. This study was an analytical, cross-sectional, prospective, observational design. The following cognitive tests were used for cognitive assessment: 1) an adapted version of the Face-Name Associative Memory Exam (FNAME-12A), 2) the daily life memory questionnaire (MFE-30), and 3) the Montreal Cognitive Assessment Test (MoCA). People with FED showed a mean score of 43.33 (25.40) compared to the HCtrl 19.66 (10.12) significantly higher scores (p = .05) on the MFE-30, but there were no significant differences in the FNAME. Furthermore, no significant correlations were observed between sub-jective (MFE-30) and objective (FNAME) memory performance. We observed a dissociation be-tween FED patients’ perception of memory difficulties and their objectively measured memory. These results support the idea that patients suffering from depression (even in the first episode) tend to overestimate their memory difficulties.

  • Open Access

    Daytime sleepiness and BMI exhibit gender and age differences in patients with central disorders of hypersomnolence

    by Laura Ferrazzini, Markus Schmidt, Zhongxing Zhang, Ramin Khatami, Yves Dauvilliers, Lucie Barateau, Geert Mayer, Fabio Pizza, Giuseppe Plazzi, Jari K. Gool, et al.

    Summary: The aim of the present study was to examine gender and age‐specific effects on subjective daytime sleepiness (as measured by the Epworth Sleepiness Scale), body weight and eating behaviour in patients with central disorders of hypersomnolence. Based on the European Narcolepsy Network database, we compared 1035 patients with narcolepsy type I and 505 patients with other central disorders of hypersomnolence (“narcoleptic borderland”), including narcolepsy type II (N = 308) and idiopathic hypersomnia (N = 174), using logistic regression and general linear models. In the entire study population, the Epworth Sleepiness Scale was higher in women (N = 735, mean age = 30 years, mean Epworth Sleepiness Scale = 16.6 ± SD 3.9) than in men (N = 805, mean age = 32 years, mean Epworth Sleepiness Scale = 15.8 ± SD 4.4). In women with narcolepsy type I (N = 475), both Epworth Sleepiness Scale and body mass index increased in parallel with age. In women of the narcoleptic borderland (N = 260), the Epworth Sleepiness Scale markedly peaked in their early 30s, while body mass index only started to rise at that age. This rise in body mass index following the Epworth Sleepiness Scale peak cannot be explained by sleepiness‐induced uncontrolled eating, as self‐reported uncontrolled eating was negatively associated with the Epworth Sleepiness Scale in this group. We propose that the narcoleptic borderland harbours a unique cluster of women in their fertile years with an unexplored aetiology requiring further investigation towards tailored interventions.


  • Open Access

    Effectiveness of Vortioxetine for the Treatment of Emotional Blunting in Patients with Major Depressive Disorder Experiencing Inadequate Response to SSRI/SNRI Monotherapy in Spain: Results from the COMPLETE Study

    by Michael Cronquist Christensen, Francesca Canellas, Henrik Loft, Ángel L Montejo

    Background: The multinational, open-label COMPLETE study (NCT03835715) investigated the effectiveness of vortioxetine in alleviating emotional blunting in patients with major depressive disorder (MDD) experiencing inadequate response and emotional blunting while being treated with a selective serotonin reuptake inhibitor (SSRI) or serotonin–noradrenaline reuptake inhibitor (SNRI). This paper presents results for the subgroup of patients enrolled in Spain. Methods: Patients with MDD (n = 67) experiencing partial response and emotional blunting during monotherapy with an SSRI or SNRI were switched to vortioxetine (10– 20 mg/day) for 8 weeks. The primary study outcome was emotional blunting, assessed by the Oxford Depression Questionnaire (ODQ). Results: After 8 weeks of vortioxetine, the mean (SE) change in ODQ total score from baseline was − 26.0 (2.9) (P < 0.001). Respective changes in Montgomery–Åsberg Depression Rating Scale (MADRS), Motivation and Energy Inventory, Digit Symbol Substitution Test, and Sheehan Disability Scale (SDS) total scores were − 14.9 (0.8), +34.2 (4.5), +6.3 (1.6), and ‒9.0 (1.3) (all P < 0.001 vs baseline). At week 8, 70.4% of patients no longer reported emotional blunting and 53.7% had achieved remission from their depressive symptoms (defined as a MADRS total score ≤ 10). Mediation analysis showed 77.1% of the change in SDS total score to be a direct effect of the improvement in ODQ total score after switching to vortioxetine. Adverse events were reported by 35 patients (52.2%), most commonly nausea (14 patients, 20.9%). At week 8, 33/54 patients (61.1%) were receiving vortioxetine 20 mg/day. Conclusion: In this study investigating the effectiveness of vortioxetine in Spanish patients with MDD who experienced inadequate response and emotional blunting on SSRI/SNRI monotherapy, significant improvements in emotional blunting, core depressive symptoms (including anhedonia), sleep duration, motivation and energy, cognitive performance, and overall patient functioning were observed during the 8 weeks of treatment. Two-thirds of patients no longer reported emotional blunting and over half were in remission from their depressive symptoms at week 8.


  • Open Access

    Mammalian NREM and REM sleep: Why, when and how

    by Rubén V. Rial, Mourad Akaârir, Francesca Canellas, Pere Barceló, José A. Rubiño, Aida Martín-Reina, Antoni Gamundí, M. Cristina Nicolau